Chicago, IL – June 16, 2025 – Zacks.com releases the list of companies likely to issue earnings surprises. This week’s list ...

QIAGEN N.V. QGEN recently announced a new global collaboration with Incyte INCY. The partnership enhances QIAGEN’s onco-hematology diagnostics pipeline and supports Incyte’s extensive portfolio in ...

Investing in today’s dynamic market requires a keen eye for value, and Hims & Hers Health, Inc. ($HIMS) has been catching attention with its explosive ...

Discover why Hims & Hers is leading the telehealth market with strong growth, a loyal user base, and expansion into new ...

Hims & Hers Health, Inc. (HIMS) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look ...

Eli Lilly found itself in a pharmaceutical pickle after its CFO claimed telehealth partners don’t compound key weight-loss ...

Eli Lilly will partner only with telehealth firms that agree to stop selling compound versions of its drug Zepbound or Novo Nordisk’s Wegovy, a move that sidelines Hims & Hers Health, Bloomberg ...

Whether you want a medicated solution or an all-natural fix, these pro-backed recommendations can start helping in as little ...

Officials at the FDA say they want to speed up approvals for new drugs and devices using tech like the new "Elsa" AI system. More news is on other uses of AI in health care, Eli Lilly refusing to work ...

Hims & Hers leverages ZAVA's expertise to enter Europe's weight-loss market, boosting growth and profitability. Read what ...

Hims & Hers (NYSE: HIMS) stock, a prominent player in the booming telehealth sector, has undeniably captured significant investor attention recently. Perhaps you, like many others, have been caught up ...

NEW YORK CITY, NY / ACCESS Newswire / June 10, 2025 / PointFive, a leading innovator of cloud management and pioneer of Cloud ...